Ortivus AB ser. B (ORTI-B) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Ortivus AB ser. B (ORTI-B) has a cash flow conversion efficiency ratio of -0.529x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-11.86 Million ≈ $-1.28 Million USD) by net assets (Skr22.41 Million ≈ $2.41 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ORTI-B equity to assets ratio to measure how much of total assets are equity-financed.
Ortivus AB ser. B - Cash Flow Conversion Efficiency Trend (2003–2025)
This chart illustrates how Ortivus AB ser. B's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Ortivus AB ser. B earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
Ortivus AB ser. B Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ortivus AB ser. B ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Rocketdna Ltd
AU:RKT
|
-0.192x |
|
Sensei Biotherapeutics Inc
NASDAQ:SNSE
|
-0.056x |
|
Predictive Oncology Inc
NASDAQ:POAI
|
0.021x |
|
Devonian Health Group Inc
V:GSD
|
-0.675x |
|
Prostar Holdings Inc
V:MAPS
|
-0.535x |
|
TAG Oil Ltd.
V:TAO
|
-0.021x |
|
Wonlim Corp.
KO:005820
|
-0.016x |
|
Dignitana AB
ST:DIGN
|
-0.115x |
Annual Cash Flow Conversion Efficiency for Ortivus AB ser. B (2003–2025)
The table below shows the annual cash flow conversion efficiency of Ortivus AB ser. B from 2003 to 2025. For the full company profile with market capitalisation and key ratios, see Ortivus AB ser. B market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr22.41 Million ≈ $2.41 Million |
Skr-25.24 Million ≈ $-2.72 Million |
-1.126x | -182.77% |
| 2024-12-31 | Skr-7.17 Million ≈ $-771.07K |
Skr-9.75 Million ≈ $-1.05 Million |
1.360x | +7869.33% |
| 2023-12-31 | Skr17.30 Million ≈ $1.86 Million |
Skr-303.00K ≈ $-32.61K |
-0.018x | +90.98% |
| 2022-12-31 | Skr35.44 Million ≈ $3.81 Million |
Skr-6.88 Million ≈ $-740.18K |
-0.194x | -173.52% |
| 2021-12-31 | Skr29.44 Million ≈ $3.17 Million |
Skr7.77 Million ≈ $836.61K |
0.264x | -72.11% |
| 2020-12-31 | Skr19.68 Million ≈ $2.12 Million |
Skr18.63 Million ≈ $2.00 Million |
0.947x | +336.12% |
| 2019-12-31 | Skr8.75 Million ≈ $942.07K |
Skr-3.51 Million ≈ $-377.73K |
-0.401x | -71.47% |
| 2018-12-31 | Skr2.18 Million ≈ $234.71K |
Skr-510.00K ≈ $-54.88K |
-0.234x | +69.43% |
| 2017-12-31 | Skr15.55 Million ≈ $1.67 Million |
Skr-11.90 Million ≈ $-1.28 Million |
-0.765x | -180.94% |
| 2016-12-31 | Skr5.22 Million ≈ $561.97K |
Skr4.93 Million ≈ $531.08K |
0.945x | +444.95% |
| 2015-12-31 | Skr12.36 Million ≈ $1.33 Million |
Skr-3.39 Million ≈ $-364.50K |
-0.274x | -116.60% |
| 2014-12-31 | Skr19.35 Million ≈ $2.08 Million |
Skr31.93 Million ≈ $3.44 Million |
1.651x | +498.55% |
| 2013-12-31 | Skr17.21 Million ≈ $1.85 Million |
Skr-7.13 Million ≈ $-767.09K |
-0.414x | -244.38% |
| 2012-12-31 | Skr31.19 Million ≈ $3.36 Million |
Skr8.95 Million ≈ $962.73K |
0.287x | +195.85% |
| 2011-12-31 | Skr29.03 Million ≈ $3.12 Million |
Skr-8.69 Million ≈ $-934.97K |
-0.299x | +24.94% |
| 2010-12-31 | Skr66.95 Million ≈ $7.20 Million |
Skr-26.69 Million ≈ $-2.87 Million |
-0.399x | -235.70% |
| 2009-12-31 | Skr84.63 Million ≈ $9.11 Million |
Skr-10.05 Million ≈ $-1.08 Million |
-0.119x | +33.33% |
| 2008-12-31 | Skr106.52 Million ≈ $11.46 Million |
Skr-18.98 Million ≈ $-2.04 Million |
-0.178x | -1980.44% |
| 2007-12-31 | Skr163.02 Million ≈ $17.54 Million |
Skr-1.40 Million ≈ $-150.23K |
-0.009x | +95.21% |
| 2006-12-31 | Skr226.03 Million ≈ $24.32 Million |
Skr-40.42 Million ≈ $-4.35 Million |
-0.179x | -126.19% |
| 2005-12-31 | Skr229.72 Million ≈ $24.72 Million |
Skr-18.16 Million ≈ $-1.95 Million |
-0.079x | -131.94% |
| 2004-12-31 | Skr224.47 Million ≈ $24.16 Million |
Skr55.57 Million ≈ $5.98 Million |
0.248x | -8.52% |
| 2003-12-31 | Skr225.09 Million ≈ $24.22 Million |
Skr60.91 Million ≈ $6.55 Million |
0.271x | -- |
About Ortivus AB ser. B
Ortivus AB (publ) develops and commercializes medical technology solutions and e-health for healthcare industry in Sweden and internationally. The company offers MobiMed Monitor that monitor and shares vital signs and ECG; MobiMed ePR, an electronic patient record system for documentation of treatment and events; MobiMed enRoute, a navigation, case management, and mass casualty management; MobiMe… Read more